Table 1.

Baseline Conditions of Patients With Decrease in LGE vs Patients With No Change or Increase in LGE

Patients With Decrease in LGE After 3 mo (n=16)Patients With No Change or Increase in LGE After 3 mo (n=8)
Mean age (SD)36 (18)36 (13)
Male sex, n (%)14 (88)4 (50)
Body mass index, mean, kg/m2 (SD)26 (4)28 (6)
Smoker, n (%)8 (50)2 (25)
CAD, n (%)3 (19)0 (0)
Hypertension, n (%)5 (31)1 (12.5)
Dyslipidemia, n (%)4 (25)1 (12.5)
Diabetes mellitus, n (%)2 (12.5)0 (0)
CMR data, baseline
 Mean LVEF by CMR, % (SD)55 (6)55 (7)
 LGE % of LV myocardial volume (SD)15 (9)11 (10)
 Pericardial involvement by CMR, n (%)13 (81)6 (75)
 Edema by CMR, n (%)8 (50)4 (50)
CMR data, 3 mo
 Mean LVEF by CMR, % (SD)57 (3)54 (5)
 LGE % of LV myocardial volume (SD)6 (7)13 (12)
 Pericardial involvement by CMR, n (%)0 (0)1 (12.5)
 Edema by CMR, n (%)0 (0)1 (12.5)
Medications on admission n, (%)
 β-Blocker2 (12.5)1 (12.5)
 ACE inhibitor2 (12.5)0 (0)
 ARB1 (6)0 (0)
 MR antagonist0 (0)0 (0)
 Diuretics1 (6)0 (0)
 NSAID/colchicine0 (0)0 (0)
Medications at discharge, n (%)
 β-Blocker8 (50)2 (25)
 ACE inhibitor8 (50)3 (38)
 ARB1 (6)0 (0)
 MR antagonist0 (0)0 (0)
 Diuretics1 (6)0 (0)
 NSAID7 (44)3 (38)
 Colchicine2 (12.5)0 (0)
  • ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CMR, cardiac magnetic resonance; LGE, late gadolinium enhancement; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; MR, mineralocorticoid receptor; and NSAID, nonsteroidal anti-inflammatory drug.